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Abstract Based on growing evidence linking autophagy
to preconditioning, we tested the hypothesis that autoph-
agy is necessary for cardioprotection conferred by
ischemic preconditioning (IPC). We induced IPC with
three cycles of 5 min regional ischemia alternating with
5 min reperfusion and assessed the induction of autoph-
agy in mCherry-LC3 transgenic mice by imaging of
fluorescent autophagosomes in cryosections. We found a
rapid and significant increase in the number of autopha-
gosomes in the risk zone of the preconditioned hearts. In
Langendorff-perfused hearts subjected to an IPC protocol
of 3×5 min ischemia, we also observed an increase in
autophagy within 10 min, as assessed by Western
blotting for p62 and cadaverine dye binding. To establish
the role of autophagy in IPC cardioprotection, we
inhibited autophagy with Tat-ATG5
K130R, a dominant
negative mutation of the autophagy protein Atg5. Car-
dioprotection by IPC was reduced in rat hearts perfused
with recombinant Tat-ATG5
K130R. To extend the potential
significance of autophagy in cardioprotection, we also
assessed three structurally unrelated cardioprotective
agents—UTP, diazoxide, and ranolazine—for their ability
to induce autophagy in HL-1 cells. We found that all three
agents induced autophagy; inhibition of autophagy abol-
ished their protective effect. Taken together, these findings
establish autophagy as an end-effector in ischemic and
pharmacologic preconditioning.
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Introduction
Thereisincreasingevidencethattheinductionofautophagyis
associated with attenuation of ischemia/reperfusion (I/R)
injury[1]. A number of known cardioprotective interventions
have subsequently been shown to trigger autophagy, includ-
ing rapamycin [2], caloric restriction [3], exercise [4], nitric
oxide [5], and lipopolysaccharide [6]. A number of different
pharmacologic agents have been shown to mimic ischemic
preconditioning to achieve cardioprotection, including aden-
osine and various adenosine receptor agonists, purinergic
receptor agonists such as UTP, the mitochondrial ATP-
sensitive potassium channel (mitoKATP), and various cyto-
chrome P450 inhibitors (reviewed in [7]). We previously
demonstrated a requirement for autophagy in cardioprotec-
tion mediated by the adenosine A1 agonist 2-chloro-
cyclopentyladenosine (CCPA) and the cytochrome P450
inhibitor sulfaphenazole [8, 9]. Despite a reported association
between IPC and autophagy [10–12], whether autophagy is
an essential mediator of protection conferred by IPC remains
to be established.
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is a cellular housekeeping process essential for removal
of protein aggregates and damaged or unwanted organ-
elles [13]. The process involves two parallel ubiquitin
ligase-like systems: Atg12 must be conjugated onto Atg5;
this step is essential for the subsequent conjugation of
LC3 onto phosphatidylethanolamine in the growing
autophagosomal membrane (reviewed in [7]). The coordi-
nate action of these systems results in formation of
autophagosomes which are recruited to engulf targets
through the action of adapter proteins such as p62. The
mature autophagosome transports its cargo to the lyso-
some for degradation and export of the breakdown
products which include amino acids, carbohydrates,
nucleic acids, and fatty acids. A variety of signals can
induce autophagy, including protein kinase C, reactive
oxygen species (ROS), nitric oxide (NO), and AMPK.
AMPK can inhibit mTOR, which is a powerful negative
regulator of autophagy. Many of the signal transduction
pathways that trigger autophagy appear to overlap with
those known to signal preconditioning. For these reasons,
we decided to investigate whether ischemic precondition-
ing would induce autophagy and whether autophagy is
required for cardioprotection mediated by preconditioning.
Materials and Methods
In Vivo Studies of Autophagy and Preconditioning We used
transgenic mice expressing the fusion protein mCherry-LC3
under the alpha myosin heavy chain promoter to study
autophagy in vivo. We have previously described these
mice [8, 9, 14, 15]. Anesthetized mCherry-LC3 transgenic
mice were subjected to regional ischemic preconditioning
(three cycles of 5 min ischemia alternating with 5 min
reperfusion); 1 h later, hearts were removed and cryosec-
tioned. To quantitate autophagosomes, cryosections were
washed with PBS for 5 min then briefly fixed with 4%
paraformaldehyde. Using the 60× lens, mCherryLC3 red
dots were counted, and density per unit area in ten fields
were determined. Three hearts were analyzed per condition.
Langendorff Perfusion The isolated perflused rat heart
model was utilized as previously described [16, 17]. In
brief, after anesthesia and heparinization (pentobarbital
sodium 60 mg/kg i.p. and heparin 500 U i.p.), rat hearts
were excised into ice cold Krebs–Henseleit solution and
perfused with oxygenated buffer within 30 s. Hearts were
perfused with buffer at 37°C at constant pressure
(60 mmHg) for 5 min for stabilization. Where indicated,
Tat-ATG5
K130R (∼200 nM) or Tat-beta-galactosidase (Tat-
β-gal, ∼200 nM) was administered for 15 min, followed by
a buffer change before ischemic preconditioning (3×5 min
global no-flow ischemia). Tat-ATG5
K130R was prepared by
cloning ATG5
K130R into the pHA-Tat construct previously
described [18]. Recombinant protein was purified as
previously described [18–20]. For determination of autoph-
agy, hearts were processed immediately after the IPC
treatment. In other studies, following protein infusion and/
or IPC, global no-flow ischemia was maintained for
1 2 0m i n .C Kr e l e a s ew a sm e a s u r e dd u r i n gt h ef i r s t
15 min of reperfusion using the CK EC 2.7.3.2 UV test
kit (Stanbio Laboratory, Boerne, TX, USA). After 2-
h reperfusion, infarct size was assessed by triphenyl
tetrazolium chloride staining [17]. Other biochemical
analyses of ischemic and reperfused heart tissue were
performed on hearts flash-frozen in liquid nitrogen at the
times indicated. All procedures were approved by the
Animal Care and Use Committee at San Diego State
University and conform to the Guide for the Care and
Use of Laboratory Animals (National Institutes of Health
publication no. 85-23, revised 1996).
Isolation of Protein Fractions Frozen heart samples were
thawed on ice in homogenization buffer containing (in
mmol/L) Tris–HCl 50, NaCl 100, EDTA 1, EGTA 1, 1%
Triton X-100, and protease inhibitor cocktail (Roche)). The
tissue was minced and Polytron homogenized (Kinematica,
Basel, Switzerland) on ice for 15 s for three passes. The
homogenates were centrifuged at 600 g for 5 min at 4°C,
and the supernatant was centrifuged at 10,000 g for 10 min
at 4°C. The supernatant, designated as crude cytosol, was
divided with aliquots stored at −80°C.
Western Blot Analysis Proteins prepared from rat hearts
were quantified by Bio-Rad protein assay. For immunode-
tection, 50 µg of crude cytosol prepared as above were
resolved on SDS-PAGE 10% denaturing gels and trans-
ferred to PVDF nylon membranes. The membranes were
blocked with 5% nonfat dry milk in TNT buffer (in mM:
NaCl 100, Tris–HCl 10 (pH 7.4), and 0.1% Tween-20) for
1 h. The blots were then incubated with 200-fold diluted
primary antibodies against LC3B-II (Cell Signaling Tech-
nology, Beverly, MA, USA) and p62 (BD Biosciences, San
Jose, CA, USA) at 4°C overnight and then washed with
TNT buffer at room temperature and incubated with
appropriate peroxidase-conjugated secondary antibody
(1:2,000 dilution). Immunoreactive bands were visualized
by chemiluminescence (ECL kit, Amersham, Indianapolis,
IN, USA) on X-ray film. Each immunoblotting experiment
was repeated three to five times, and the results were
averaged. To quantify the protein, intensity of bands was
assessed with Scion Image Software.
Measurement of Autophagy by Cadaverine Uptake Lan-
gendorff-perfused rat hearts were minced in homogeni-
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10 mM HEPES, pH 7.0, plus fresh protease inhibitors) and
homogenized by Polytron for 5 s at half speed. Nuclei and
heavy membranes were removed by centrifugation at
1,000×g for 5 min at 4°C. The post-nuclear supernatant
was moved to new 1.5 mL centrifuge tubes and incubated
with Alexa Fluor 488
TM Cadaverine (Molecular Probes,
Carlsbad, CA, USA) at 25 μM final concentration for
10 min. The samples were spun at 20,000×g for 20 min at
4°C and the pellet washed twice with resuspension buffer
(140 mM KCl, 10 mM MgCl2,5m MK H 2PO4,1m M
EGTA, 10 mM MOPS, pH 7.4 plus fresh protease
inhibitors). The pellet was resuspended in 350 μLr e s u s -
pension buffer and the fluorescence intensity read on a 96-
well plate reader at excitation/emission 495/519 nm in
triplicate. The relative fluorescence units were standard-
ized to the protein concentration of each sample which
was determined by Bradford assay (Pierce, Rockford, IL,
USA).
HL-1 Cell Culture Cells of the murine atrial-derived
cardiac cell line HL-1 [21] were plated in gelatin/fibronec-
tin-coated culture vessels and maintained in Claycomb
medium [21] (JRH Biosciences, Lenexa, KS, USA)
supplemented with 10% fetal bovine serum, 0.1 mm
norepinephrine, 2 mm L-glutamine, 100 U mL
−1 penicillin,
100 UmL
−1 streptomycin, and 0.25 µg mL
−1 amphotericin
B. HL-1 cells were transfected with the indicated vectors
using the transfection reagent Effectene (Qiagen, Valencia,
CA, USA), according to the manufacturer’s instructions,
achieving at least 40% transfection efficiency, as scored by
the percentage of cells expressing GFP-LC3 (either diffuse
or punctate distribution). The dominant negative pmCher-
ryATG5
K130R was previously described [22] and has been
deposited with Addgene (www.addgene.org). For adult
cardiomyocytes, GFP-LC3 infected cells were incubated
with recombinant Tat-ATG5
K130R for 30 min before adding
50 μM UTP, 100 μM DZX, or 1 μM ranolazine. For
simulated ischemia/reperfusion (sI/R) studies, cells were
plated in 14-mm diameter glass bottom microwell dishes
(MatTek, Ashland, MA, USA), and ischemia was intro-
duced by a buffer exchange to ischemia-mimetic solution
(in mM: 20 deoxyglucose, 125 NaCl, 8 KCl, 1.2 KH2PO4,
1.25 MgSO4, 1.2 CaCl2, 6.25 NaHCO3, 5 sodium lactate,
20 HEPES, pH 6.6) and placing the dishes in hypoxic
pouches (GasPak
TM EZ, BD Biosciences, San Jose, CA,
USA) equilibrated with 95% N2,5 %C O 2. After 2 h of
simulated ischemia, reperfusion was initiated by a buffer
exchange to normoxic MKH buffer and incubation at 95%
room air, 5% CO2. Controls incubated in normoxic MKH
buffer were run in parallel for each condition for periods of
time that corresponded with those of the experimental
groups.
To analyze autophagy in cell culture, cells were inspected at
60× magnification and classified as: (a) cells with predom-
inantly diffuse GFP–LC3 fluorescence or as (b) cells with
numerous GFP–LC3 puncta (>30 dots/cell), representing
autophagosomes. At least 200 cells were scored for each
condition in three or more independent experiments.
Protein content and LDH activity were determined accord-
ing to El-Ani et al. [23]. Briefly, 25 μL supernatants from
35 mm dishes were transferred into wells of a 96-well plate,
and the LDH activities were determined with an LDH-L kit
(Sigma, St. Louis, MO, USA), according to the manufac-
turer. The product of the enzyme was measured spectro-
photometrically at 30°C at a wavelength of 340 nm as
described previously [24]. The results were expressed
relative to the control (X-fold) in the same experiment.
Each experimental condition was done in triplicate, and the
experiments were repeated at least three times.
Statistical Analysis Statistical analysis was performed
between groups by ANOVA by using INSTAT 4.10
software (GraphPad, La Jolla, CA, USA). A P value
<0.05 was considered significant.
Results
Ischemic Preconditioning Induces Autophagy
To assess autophagy, mCherry-LC3 transgenic mice
were anesthetized and subjected to 3×5 min LAD
ligation to induce IPC. One hour later, hearts were
removed and autophagy was assessed by fluorescence
microscopy. IPC increased the number of mCherry-LC3-
labeled autophagosomes in the area at risk (Fig. 1a and b).
We also measured autophagy by the cadaverine dye
binding assay. As shown in Fig. 1c, IPC resulted in
increased levels of dye binding, consistent with upregula-
tion of autophagy.
We then assessed autophagy in the Langendorff model.
Isolated perfused rat hearts were subjected to 3×5 min
global no-flow ischemia alternating with reperfusion. After
the third cycle, autophagy was measured by cadaverine dye
binding and Western blot for p62, a key autophagy protein
which is known to be upregulated in response to oxidative
stress [25]. Although p62 accumulates in tissues in
association with ubiquitinated protein aggregates when
autophagy is chronically suppressed [26], protein levels of
p62 can rise acutely in response to oxidative stress or other
stimuli [25]. We have observed an acute (within 10 min)
upregulation of Beclin1 and LC3, as well as p62, in hearts
subjected to a pharmacologic preconditioning agent (un-
published data). Autophagy was increased immediately
J. of Cardiovasc. Trans. Res. (2010) 3:365–373 367after IPC, as indicated by increased cadaverine dye binding
(Fig. 2a) and increased p62 protein (Fig. 2b).
Autophagy is Required for Cardioprotection by IPC
In order to establish the role of autophagy in IPC-mediated
cardioprotection, we used the specific inhibitor of autoph-
agy, Tat-ATG5
K130R in Langendorff-perfused rat hearts.
Tat-β-gal was used as a protein control. Hearts were treated
for 15 min and then subjected to IPC (3×5 min global no-
flow ischemia alternating with reperfusion) followed by
30 min global no-flow ischemia and 2 h reperfusion
(Fig. 3a). Control hearts subjected to I/R had infarcts
averaging 42% of the area at risk (Fig. 3b). Hearts
subjected to IPC in the presence of the control protein
(Tat-β-gal) were protected against I/R injury, with an
average infarct size of 20% (Fig. 3b). In contrast, hearts
pretreated with the autophagy inhibitor Tat-ATG5
K130R had
larger infarcts, indicating that IPC was significantly less
effective when autophagy was inhibited. In the absence of
IPC, Tat-ATG5
K130R had no effect on infarct size.
Autophagy is Involved in Cytoprotection Mediated
by Diazoxide, Utp, and Ranolazine
We selected three structurally diverse cardioprotective agents
to ascertain their ability to induce autophagy in cardiomyo-
cytes.WepreviouslyreportedthatHL-1cellsbehavesimilarly
to adult rat cardiomyocytes in response to simulated I/R and
the cardioprotective agents CCPA and sulfaphenazole [8, 9].
Diazoxide, UTP, and ranolazine all increased autophagy
rapidly (Figs. 4a and 5a). Transient transfection with
ATG5
K130R suppressed autophagy induced by these agents
(Fig. 4a). To determine the requirement for autophagy in
cytoprotection by these agents, we transfected HL-1 cells
with ATG5
K130R and 24 h later subjected them to sI/R in the
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Fig. 1 Autophagy is induced by
IPC in vivo. a mCherry-LC3
mice were subjected to three
cycles of 5 min LAD occlusion
alternating with 5 min reperfu-
sion. One hour later, hearts were
harvested and cryosections were
prepared. b Quantification of
autophagosomes (red puncta)
from cryosections of sham-
operated hearts, preconditioned
hearts in the risk regions (IPC),
and in the nonrisk (non-IPC)
regions. Ten representative
fields were scored for three
hearts per condition (P<0.05,
N=3). c. Quantification of
autophagy by cadaverine dye-
binding assay (P<0.05, N=3)
368 J. of Cardiovasc. Trans. Res. (2010) 3:365–373presence or absence of the cardioprotective drugs. As shown
in Fig. 4b, inhibition of autophagy by ATG5
K130R abolished
cytoprotection by ranolazine, UTP, and diazoxide, agents
which elicit cytoprotection via diverse signaling pathways.
Specifically, treatment with ATG5
K130R prior to exposing the
cells to the cardioprotective drugs resulted in LDH release
levels comparable to that associated with ischemia alone.
Similarly, studies in adult cardiomyocytes infected with
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J. of Cardiovasc. Trans. Res. (2010) 3:365–373 369adenovirus for GFP-LC3 revealed that CCPA, UTP, and
diazoxide induced autophagy which was suppressed by Tat-
ATG5
K130R (Fig. 5b).
Discussion
We studiedthe roleofautophagyinischemicpreconditioning.
Ischemic preconditioning involves intracellular signaling
through G-protein coupled receptors and a diverse array of
protein kinases including protein kinase C and Akt [27]. The
putative mitochondrial ATP-sensitive potassium channel
(mitoKATP), production of nitric oxide, and ROS are also
consistent features of IPC [5, 28]. To extend the potential
significance of autophagy in cardioprotection beyond ische-
mic preconditioning, we also examined three structurally
unrelated cardioprotective agents, which are as follows: UTP
[29], diazoxide [30], and ranolazine [31]. UTP binds to a
purinergic receptor that shares downstream signaling with
adenosine [32]. Diazoxide has been suggested to directly
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Fig. 4 Cardioprotective agents involve autophagy in HL-1 cells. a
Autophagy was scored in GFP-LC3-transfected HL-1 cells exposed to
the indicated agents for 10 min. Where indicated, cells were
cotransfected with the autophagy inhibitor ATG5
K130R. b HL-1 cells
were transfected with GFP-LC3 and with or without ATG5
K130R then
subjected to simulated ischemia in the presence or absence of the
indicated drug. At the end of 2-h simulated ischemia, cell culture
supernatant was harvested for LDH determination
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ROS production and activation of protein kinase C [33].
Ranolazine is a sodium channel inhibitor that also interferes
with fatty acid oxidation and may have unknown effects on
other cardioprotective signaling pathways [34, 35]. In the
present study, we demonstrate that ischemic preconditioning
is associated with increased autophagosome formation in
vivo and ex vivo. We also demonstrate the upregulation of
autophagy by UTP, diazoxide, and ranolazine, although the
signal transduction pathway leading to autophagy remains to
be elucidated. Our study demonstrates that inhibition of
autophagy attenuates their protective effects, and supports
the concept that autophagy is an important element of
cardioprotection.
Autophagy has long been recognized to occur in cardiac
tissue. Decker and Wildenthal observed that induction of
autophagy correlated with functional recovery of the rabbit
heart after I/R and noted that prolonged ischemia appeared to
impair the autophagosome-lysosomal pathway, which corre-
lated with irreversible damage and contractile dysfunction
[36]. Vatner’s group reported increased expression of several
autophagy-related genes in the chronically ischemic myocar-
dium [37] and suggested it might protect against apoptosis.
Subsequently, several groups have shown that autophagy is
increased in the setting of ischemic or pharmacologic
preconditioning [8–12, 38] and have suggested that it serves
a protective function. Interestingly, a number of agents that
have been shown to be cardioprotective may also involve the
Tat-Atg5K130R
Normoxia
CCPA
UTP
DZX
UTP
CCPA
DZX
Normoxia
Con
Diazoxide
Ranolazine
UTP
Control
HL-1 cells ab
Fig. 5 Modulation of autophagy by pharmacologic agents and Tat-
ATG5
K130R. a HL-1 cells were transfected with GFP-LC3 and treated
with the indicated drugs for 10 min. Representative images of treated
cells are shown. b Adult rat cardiomyocytes were infected with
adenovirus for GFP-LC3 and treated with or without Tat-ATG5
K130R
before adding the indicated drugs for 10 min. Representative images
of cells are shown
J. of Cardiovasc. Trans. Res. (2010) 3:365–373 371induction of autophagy, including rapamycin [2, 22],
hydrophobic statins [39, 40], lipopolysaccharide [6, 14, 41],
and chloramphenicol [42]. The requirement for autophagy in
cardioprotection has been established for the adenosine A1
agonist CCPA [8], the cytochrome P450 inhibitor sulfaphe-
nazole [9], and in this study, IPC.
Direct demonstration of a requirement for autophagy in
preconditioning has been limited by the lack of specific
tools to inhibit autophagy. In order to overcome this and
definitively establish the requirement for autophagy, we
used a cell-permeable agent to specifically inhibit autoph-
agy, Tat-ATG5
K130R. We previously showed that Tat-
ATG5
K130R effectively inhibits autophagy in the isolated
perfused heart model and partially abrogated cardioprotec-
tion by sulfaphenazole [9]. In this study, we again observed
a partial loss of protection by preconditioning in the Tat-
ATG5
K130R-infused hearts. This raises the possibility of an
unrelated mechanism of protection.
The stressed heart may benefit from amino acids,
carbohydrates, and fatty acids generated by autophagic
degradation of cellular proteins, lipids, and glycogen
granules. Several studies have shown that blocking lyso-
somal fusion in fasted animals result in plummeting ATP
levels in the heart, suggesting that production of metabolic
substrates is important, at least in the setting of fasting [43].
Autophagy might also improve ion homeostasis by exporting
protons via vacuolar proton ATPase pumping into lysosomes.
This would limit the need for Na
+/H
+ exchange and would
thereby limit secondary Ca
++ overload (via Na
+/Ca
++
exchange). Consistent with this notion, we previously
showed that inhibition of the VPATPase disrupted cytopro-
tection and ion homeostasis associated with ischemic
preconditioning [44, 45]. Limiting calcium overload might
avoid triggering the mitochondrial permeability transition, a
critical phenomenon leading to ischemic cell death.
The heart is critically dependent on autophagy for
normal homeostasis as well as the response to stress. Our
results reveal autophagy to be an important element of the
endogenous defense mechanisms activated by ischemic
preconditioning. Identification of agents that can rapidly
induce autophagy could lead to novel cardioprotective
drugs. IPC and pharmacologic agents have shown promise
in animal studies, but many have failed in the clinical
setting [46]. In part, this may be due to the fact that most
preclinical studies use young, healthy animals, whereas
clinical studies involve patients with underlying diseases
including metabolic syndrome, diabetes, hypertension, and
advanced age. Many of these conditions have been shown
to interfere with autophagy [47], which could explain the
failure of preconditioning agents in patients. In order to be
efficacious, a candidate cardioprotective drug would also
need to induce autophagy in the target population, with the
appropriate timing and magnitude of response. The key
finding of our study is that autophagy appears to be a
common feature of cardioprotection conferred by ischemic
preconditioning and a variety of pharmacologic condition-
ing agents. Further work is needed to understand the
mechanistic basis of cardioprotection by autophagy.
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